Physostigmine, a reversible AChE inhibitor, for example, has been shown to reduce pancreatic cancer cell viability and invasion, macrophage infiltration, and pro-inflammatory signals through the inhibition of intrinsic AChE activity [56]. This evidence concerns the gene ACHE and pancreatic neoplasm.